* Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
** Arranged by type of listing and date of announcement.
*** Potential means Intention to Float (ITF) or similar announcement has been made.
**** A corporate client of Hybridan LLP.
Dish of the Day
Admissions:
None
Delistings:
None
Banquet Buffet*
London Stock Exchange: Main Market and AIM
Abingdon Health 10.75p £26.54m (ABDX.L)
The international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tech, announces that Abingdon Analytical Ltd, the Company’s Doncaster based performance evaluation laboratory, has been granted accreditation to ISO/IEC 17025:2017 by the UK Accreditation Service. ISO/IEC 17025 is the international standard for testing and calibration laboratories that assesses whether a laboratory can consistently produce valid, reliable and defensible results. Accreditation gives the customers an independently assessed basis for confidence in studies performed within scope. It also strengthens Abingdon Health's end-to-end offering; from diagnostic development and manufacturing through to regulatory support and market access.
Alien Metals Limited 0.07p £8.56m (UFO.L)
The minerals exploration and development Company announces that its joint venture partner in the Elizabeth Hill Silver Project, West Coast Silver Limited (ASX: WCE), has today announced its H2 2026 diamond drilling program at the high-grade Elizabeth Hill Silver Project in Western Australia is scheduled to commence in early to mid-October. The 18 diamond hole drill program for ~1,800m is commencing across the Elizabeth Hill Silver Project, aiming to advance mineral resource definition, extension and new high-grade zone definition commenced in H1 2026. West Core Drilling is scheduled to mobilise in the week of 5 October, with drilling expected to continue through early to mid-December. New drilling results will be included in a March 2027 MRE update and Q1 2027 Scoping Study outcomes. A separate MRE update remains scheduled for November 2026.
Braemar 234.00p £74.40m (BMS.L)
The provider of expert chartering, investment and risk management advice to the shipping and energy markets announces a trading update for the six months ended 31 August. Revenue was up 16% to £74.3m (HY26: £63.9m) driven by a strong rate environment, while underlying operating profit was up 7% to £6.0m (HY26: £5.6m), after making £1.4m of strategic investments to drive future growth. Net debt reduced to zero as at 31 August (HY26: £5.6m). The board remains confident that the Braemar will deliver in line with market expectations for the full year. Increased volatility across shipping and energy markets has lifted average rates in the chartering business and underpins strong demand for the advisory and risk management services.
ECR Minerals 0.17p £6.37m (ECR.L)
The gold exploration and development Company focused on Australia announced that it has agreed revised payment terms in respect of the A$2m deferred cash consideration relating to its acquisition of a 50% interest in the Maddens Gold Project in North Queensland. Under the original terms, as announced by the Company on 18 May, the A$2m cash consideration was payable to certain vendor shareholders of Lucky Strike Mining Ventures Pty Ltd six months following completion of the acquisition and would therefore have fallen due in November 2026. The payment of the A$2m deferred cash consideration will instead be contingent upon ECR Minerals (Paleogold) Ltd receiving corresponding proceeds from gold production and sales from Maddens. Accordingly, there is no longer a fixed requirement for ECR to make the A$2m cash payment in November 2026 and this payment now does not have a fixed repayment timeline.
MobilityOne Limited 8.50p £8.5m (MBO.L)
The e-commerce infrastructure payment solutions and platform provider announces its unaudited interim results for the six months ended 30 June. Revenue decreased by 2.0% to £113.7m (H1 2025: £116.0m), mainly due to lower contributions from core products and services in Malaysia, including mobile prepaid airtime reloads and bill payment services, during H1 2026 as compared to the corresponding period in 2025. Loss after tax for H1 2026 was £1.02m, compared to a loss after tax of £1.14m in H1 2025. MobilityOne Limited expects the business environment to remain challenging and will continue to adopt a cautious approach towards the outlook for the remainder of 2026. MobilityOne also expects the proposed joint venture with Super Apps Holdings Sdn Bhd and the proposed merger exercise of Technology & Telecommunication Acquisition Corporation and Super Apps to complete in the near term following which the Group will receive the first payment of the consideration of RM40.0m (c. £6.84m) in cash.
Pennant International Group (UK) Ltd 32.00p £14.29m (PEN.L)
The systems support software and training solutions Company has secured a series of new Auxilium software contracts with end users in the US defence sector through its Siemens channel partnership to a major US defence end user. The contracts, which have now been executed, are expected to generate aggregate recurring revenue in excess of US$300k per annum. As a result, the Group's Annualised Recurring Revenue (ARR) has increased to approximately £3.1m, exceeding the £3.0m ARR target for the end of 2026 set out in the Group's January 2026 trading update.
Panther Metals 152.5p £17.1m (PALM.L)*
The mineral exploration Company has completed its registration with the US Federal System for Award Management (SAM.gov) and has been successfully issued with a Unique Entity Identifier. Panther has also been issued a NATO Commercial and Government Entity code through the UK Ministry of Defence. These registrations provide Panther with the identifiers required to engage directly in relevant U.S. Government procurement and funding opportunities and represent another practical step in positioning the Company within the North American critical minerals supply chain. The Company is currently advancing engagement in relation to its project portfolio in Ontario, Canada, where the Company believes the scale of one opportunity already has the potential to be strategically significant to long-term North American critical mineral supply.
Rockfire Resources 0.11p £11.46m (ROCK.L)
The base metal, critical mineral and precious metal exploration Company provided the market with a drilling and operational update from Rockfire’s 100%-owned Molaoi zinc deposit in Greece, with a maiden JORC Inferred germanium mineral resource estimation commencing. GeoRes Mining Consultants have started a maiden Inferred germanium resource estimate, which will include an updated Inferred zinc resource. To track the germanium resource progression, the Company has elected to commence the estimation early. It is expected that the resource numbers will be announced within the next four weeks.
Thalia Therapeutics 0.63p £10.65m (THAT.L)
The clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease announces the granting and issue of a Chinese patent relating to miRisten (THAT-001), its clinical-stage programme for acute myeloid leukaemia. The patent covers the use of miRisten in the highly valuable Chinese market. It further enhances the intellectual property exclusively licensed from City of Hope, one of the largest and most advanced cancer research and treatment organisations in the U.S., to Sanmirna Therapeutics Inc., which Thalia acquired in July 2026, with patents granted in the US, UK, Germany, France, Japan, EPO (European Patent Organisation) countries, and now in China.
AQSE Market:
Time to Act 45.00p £9.89m (TTA.L)
The Aquis-quoted specialist engineering Company announced audit clearance for its results for the year ended 31 March. The recorded turnover in 2026 was £2,420,068, which represents growth of 6% compared to underlying turnover for 2025 of £2,281,394. Hydrogen sector opportunities form a material and growing percentage of the turnover base. From 2022 to 2026 the Compound Annual Growth Rate in underlying turnover is 18.1%. The gross profit in 2026 was £1,663,650 with a margin of 69% compared to 2025 where gross profit was £1,073,590 with a margin of 47%. Margin increase was largely driven by a single sale of surplus coating compound executed in September 2025.
What’s baking in the oven? **
Potential IPOs:***
23rd September: Chaleit Holdings, a cyber security consultancy founded in 2021, announced its intention to list on the AIM Market. Chaleit plans to raise approximately £1.6m through a placing of new and existing ordinary shares and a direct subscription, with an anticipated market capitalisation of approximately £11.2m on Admission. The Cambridge-based company provides penetration testing and offensive security consultancy services, examining technology from an attacker’s perspective to identify vulnerabilities. Its services also include AI and language model security, cloud security, development security operations engineering, and cyber advisory and compliance work. The Company expects trading to commence on October 7, under the epic code CHA.
23rd September: Airtel Money, a scaled digital financial services platform operating across 13 African markets, has announced its intention to undertake an IPO on to the Main Market of the London Stock Exchange. As of 30 June, Airtel served approximately 53m monthly active users with a suite of mobile financial services such as micro-loans, savings accounts, insurance, wealth products. It was founded in 2011. Its growth to date has been helped by its relationship with Airtel Africa plc, its founding shareholder. Revenue reached US$1.346bn for the year ended 31 March 2026, with an EBITDA margin of approximately 50%. The Group has no external borrowings and capital expenditure represented just 3% of revenue in the year ended 31 March 2026. The IPO Offer consists solely of shares sold by existing shareholders; no new capital is being raised. The Offer will be made to qualified institutional buyers in the US and to certain institutional investors outside of the US. The Offer will also be made to retail investors in the UK through Retail Book Limited. In connection with the Offer, each of the Company, its directors and its existing shareholders are expected to agree to customary lock-up arrangements. The Prospectus is expected to be published in early October 2026 and the IPO complete mid-October 2026 with a free float of at least 10%.
Dual Listings:***
18th August: Aimia Inc. (TSX: AIM; JSE: AII) the Canadian diversified conglomerate announced plans to dual list on AIM. It owns a selection of businesses which include: (i) an 100% interest in Cortland International Inc., a global designer, manufacturer and supplier of synthetic fiber ropes, nets, slings and tethers; a 10.85% indirect stake in Clear Media Limited, the largest operator of bus shelter advertising panels in China; and iii) the Company holds a portfolio of publicly listed securities amounting C$12m as of 30 June 2026. No capital is expected to be raised on Admission and deal details remain TBC. Expected first day of dealings updated date of 29 September.
Market Movers:***
25 September: Roundhouse AI (AQSE: ETHL) The AI technology Company announcedits intention to move to AIM from AQSE. £1.5m is expected to be raised on Admission with an anticipated market capitalisation of approximately c. £14m at the Placing Price. Expected Admission date is 13th October.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
